Supportive Care in Cancer

, Volume 18, Issue 5, pp 639–646 | Cite as

Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy

  • Velia Ramírez-Amador
  • Gabriela Anaya-Saavedra
  • Erick Crespo-Solís
  • Esther Irigoyen Camacho
  • Imelda González-Ramírez
  • Sergio Ponce-de-León
Original Article



Knowledge of oral mucositis (OM) in patients with acute leukemia (AL) and chemotherapy (CT) has remained limited. Thus, a prospective, longitudinal study was undertaken to characterize clinical features, associated risk factors, and behavior of OM in a cohort of AL patients starting CT.


Prospective and longitudinal study. A cohort of patients, older than 15 years of age with AL, scheduled to receive CT, was followed from March 2006 to October 2007. At baseline and three times per week, for 21 days, patients had an oral examination performed using the Oral Mucositis Assessment Scale (OMAS); also, oral pain and difficulty to swallow were recorded using a visual analog scale. Weekly, salivary flow measurements (Schirmer’s test modified version) were done.


A cohort of 29 AL patients was followed for a median time of 21 (range, 14–53) days; 12 (41.4%) developed OM, with a mean OMAS score of 0.181 (SD ± 0.56) and a mean peak OMAS score of 1.8 (SD ± 0.56). The OM onset mean time was 9.8 (range, 2–20, SD ± 6.09) days, with a mean duration of 7 (range, 3–14, SD ± 4.15) days. OM was significantly correlated with salivary flow [rs = 0.420 (P = 0.0051)], oral pain [rs = 0.47 (P < 0.0001)], ability to swallow [rs = 0.36 (P = 0.0001)], and type of food intake [rs = 0.38 (P < 0.0001)].


OM is a frequent and early side effect of CT closely correlated with oral pain, difficulty to swallow, and impairment in food intake.


Oral mucositis Chemotherapy Acute leukemia Salivary flow 


  1. 1.
    Scully C, Sonis S, Diz PD (2006) Oral mucositis. Oral Dis 12:229–241CrossRefPubMedGoogle Scholar
  2. 2.
    Woo SB, Sonis ST, Monopoli MM, Sonis AL (1993) A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72:1612–1617CrossRefPubMedGoogle Scholar
  3. 3.
    Wardley AM, Jayson GC, Swindell R et al (2000) Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol 110:292–299CrossRefPubMedGoogle Scholar
  4. 4.
    Sonis ST (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5:3–11PubMedGoogle Scholar
  5. 5.
    Logan RM, Gibson RJ, Sonis ST, Keefe DM (2007) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43:395–401CrossRefPubMedGoogle Scholar
  6. 6.
    Köstler WJ, Hejna M, Wenzel C, Zielinski CC (2001) Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin 51:290–315CrossRefPubMedGoogle Scholar
  7. 7.
    Blijlevens N, Schwenkglenks M, Bacon P et al (2008) European blood and marrow transplantation mucositis advisory group. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26:1519–1525CrossRefPubMedGoogle Scholar
  8. 8.
    Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S (2007) Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol 5:231–235PubMedGoogle Scholar
  9. 9.
    Avritscher EB, Cooksley CD, Elting LS (2004) Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis. Semin Oncol Nurs 20:3–10CrossRefPubMedGoogle Scholar
  10. 10.
    Bolwell BJ, Kalaycio M, Sobecks R et al (2002) A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 30:587–591CrossRefPubMedGoogle Scholar
  11. 11.
    Cheng KK, Goggins WB, Lee VW, Thompson DR (2008) Risk factors for oral mucositis in children undergoing chemotherapy: a matched case-control study. Oral Oncol 44:1019–1025CrossRefPubMedGoogle Scholar
  12. 12.
    Vokurka S, Bystrická E, Koza V et al (2006) Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer 14:974–976CrossRefPubMedGoogle Scholar
  13. 13.
    Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39:91–100CrossRefPubMedGoogle Scholar
  14. 14.
    Repetto L (2003) Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1:18–24PubMedGoogle Scholar
  15. 15.
    McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI (1998) Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 34:484–490CrossRefPubMedGoogle Scholar
  16. 16.
    Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM (2004) Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 22:1268–1275CrossRefPubMedGoogle Scholar
  17. 17.
    van Kuilenburg AB, Haasjes J, Richel DJ et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:4705–4712PubMedGoogle Scholar
  18. 18.
    Mutchinick OM, López MA, Luna L, Waxman J, Babinsky VE (1999) High prevalence of the thermolabile methylenetetrahydrofolate reductase variant in Mexico: a country with a very high prevalence of neural tube defects. Mol Genet Metab 68:461–467CrossRefPubMedGoogle Scholar
  19. 19.
    Wahlin YB, Matsson L (1988) Oral mucosal lesions in patients with acute leukemia and related disorders during cytotoxic therapy. Scand J Dent Res 96:128–136PubMedGoogle Scholar
  20. 20.
    Dreizen S, McCredie KB, Bodey GP, Keating MJ (1986) Quantitative analysis of the oral complications of antileukemia chemotherapy. Oral Surg Oral Med Oral Pathol 62:650–653CrossRefPubMedGoogle Scholar
  21. 21.
    Barrett AP (1987) Clinical characteristics and mechanisms involved in chemotherapy-induced oral ulceration. Oral Surg Oral Med Oral Pathol 63:424–428CrossRefPubMedGoogle Scholar
  22. 22.
    STROBE Group. STROBE Statement. Checklist of essential items, version 3. 3.pdf. Accessed January 30, 2009.
  23. 23.
    Omura GA, Vogler WR, Lefante J et al (1982) Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy of BCG immunotherapy. Cancer 49:1530–1536CrossRefPubMedGoogle Scholar
  24. 24.
    Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A et al (2008) Acute limphoblastic leukemia: experience in adults patients treated with hyperCVAD and 0195 Protocol, at the Institute Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003–2007. Rev Invest Clin 60(6):459–469PubMedGoogle Scholar
  25. 25.
    Sonis ST, Eilers JP, Epstein JB et al (1999) Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85:2103–2113CrossRefPubMedGoogle Scholar
  26. 26.
    López-Jornet P, Camacho-Alonso F, Bermejo-Fenoll A (2006) A simple test for salivary gland hypofunction using Oral Schirmer’s test. J Oral Pathol Med 35:244–248CrossRefPubMedGoogle Scholar
  27. 27.
    Greene JC, Vermillion JR (1964) The simplified oral hygiene index. J Am Dent Assoc 68:7–13PubMedGoogle Scholar
  28. 28.
    Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300:230–235CrossRefPubMedGoogle Scholar
  29. 29.
    Matthews DE, Farewell VT (1985) Using and understanding medical statistics. Karger, BaselGoogle Scholar
  30. 30.
    Figliolia SL, Oliveira DT, Pereira MC et al (2008) Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients. Oral Dis 14:761–766CrossRefPubMedGoogle Scholar
  31. 31.
    Maiguma T, Hayashi Y, Ueshima S et al (2008) Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia. Int J Clin Pharmacol Ther 46:584–590PubMedGoogle Scholar
  32. 32.
    Raber-Durlacher JE, Weijl NI, Abu Saris M, de Koning B, Zwinderman AH, Osanto S (2000) Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer 8:366–371CrossRefPubMedGoogle Scholar
  33. 33.
    Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98:1531–1539CrossRefPubMedGoogle Scholar
  34. 34.
    Chan CW, Chang AM, Molassiotis A, Lee IY, Lee GC (2003) Oral complications in Chinese cancer patients undergoing chemotherapy. Support Care Cancer 11:48–55PubMedGoogle Scholar
  35. 35.
    Fall-Dickson JM, Ramsay ES, Castro K, Woltz P, Sportés C (2007) Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation. Clin Ther 29:2547–2561CrossRefPubMedGoogle Scholar
  36. 36.
    Elad S, Ackerstein A, Bitan M et al (2006) A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplant 37:757–762CrossRefPubMedGoogle Scholar
  37. 37.
    Shoval I, Kushner JA, Sukhu B et al (2005) The relationship between mouthrinse matrix metalloproteinases (MMP-1, 8, 13) and albumin levels with the degree of oral mucositis in allogeneic stem cell transplant patients. Bone Marrow Transplant 36:33–38CrossRefPubMedGoogle Scholar
  38. 38.
    Epstein JB, Schubert MM (1999) Oral mucositis in myelosuppressive cancer therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88:273–276CrossRefPubMedGoogle Scholar
  39. 39.
    Sung L, Tomlinson GA, Greenberg ML et al (2007) Validation of the oral mucositis assessment scale in pediatric cancer. Pediatr Blood Cancer 49:149–153CrossRefPubMedGoogle Scholar
  40. 40.
    Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMedGoogle Scholar
  41. 41.
    Cella D, Pulliam J, Fuchs H et al (2003) Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406–412CrossRefPubMedGoogle Scholar
  42. 42.
    Lara-Muñoz C, De Leon SP, Feinstein AR, Puente A, Wells CK (2004) Comparison of three rating scales for measuring subjective phenomena in clinical research. I. Use of experimentally controlled auditory stimuli. Arch Med Res 35:43–48CrossRefPubMedGoogle Scholar
  43. 43.
    Vissink A, Burlage FR, Spijkervet FK, Veerman EC, Nieuw Amerongen AV (2004) Prevention and treatment of salivary gland hypofunction related to head and neck radiation therapy and chemotherapy. Support Cancer Ther 1:111–118CrossRefPubMedGoogle Scholar
  44. 44.
    Blomgren J, Jansson S, Rödjer S, Birkhed D (2002) Secretion rate from minor salivary glands in patients with malignant haematological diseases receiving chemotherapy—a pilot study. Swed Dent J 26:75–80PubMedGoogle Scholar
  45. 45.
    Epstein JB, Tsang AH, Warkentin D, Ship JA (2002) The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94:39–44CrossRefPubMedGoogle Scholar
  46. 46.
    Ohrn KE, Wahlin YB, Sjödén PO (2001) Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 9:247–257CrossRefPubMedGoogle Scholar
  47. 47.
    Keefe DM, Schubert MM, Elting LS et al (2007) Mucositis study section of the multinational association of supportive care in cancer and the international society for oral oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMedGoogle Scholar
  48. 48.
    Epstein JB, Silverman S Jr, Paggiarino DA et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92:875–885CrossRefPubMedGoogle Scholar
  49. 49.
    Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl) 18:174–178CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Velia Ramírez-Amador
    • 1
  • Gabriela Anaya-Saavedra
    • 1
  • Erick Crespo-Solís
    • 2
  • Esther Irigoyen Camacho
    • 1
  • Imelda González-Ramírez
    • 1
  • Sergio Ponce-de-León
    • 2
  1. 1.Health Care DepartmentUniversidad Autónoma Metropolitana-XochimilcoMexico CityMexico
  2. 2.Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”Mexico CityMexico

Personalised recommendations